🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New in Phiro Tweets: Quantitative imaging metrics correlated with rapid volume loss during #radiotherapy for head & neck cancer #hncsm including high density/proliferation image markers. FDG #PET correlated with regression in uni/multivariate analysis. phiro.science/article/S2405-…

📜 In The #Laryngoscope, of #patients w #nasopharynx #cancer, stage 4 disease was most common among #Hmong, #PacificIslander, & #Black pts 👉 Improved awareness of #NPC #HNSCC needed in diverse groups 🙏 Drs @IMRTLee @SeanMMcBride @StephanieWang04 🔗 onlinelibrary.wiley.com/doi/epdf/10.10…

I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational  immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. Chiles Research Institute

1/2 March 1 already⁉️😅 🔥Absolute pleasure to be discussing BRCAness/HRD as a predictor of chemoradiosensitivity in #breastcancer with the incomparable Simon Powell MSKCC & Kerstin Borgmann UKE‼️ 🙏 to Sue Yom My first #radbio podcast😊 🧵Tweetorial soon ....

2/2 IJROBP - The Red Journal Podcast: Redjournal page: redjournal.org/audio-do/red-j… Apple podcast page: podcasts.apple.com/us/podcast/ast… Article: redjournal.org/article/S0360-… Editorial: redjournal.org/article/S0360-…

NEW from #KaramLab #Jake Gadwa @WUSTLDBBS WUSTL Immunology TME dictates response to RT-IO: jitc.bmj.com/content/jitc/1… Tumor response vs progression using identical radiation-immunotherapy regimen is independent of cancer cell type but rather mediated by the TME & Tregs accumulation

📜 I am honored to share our work, "Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis," published in The Lancet Oncology. 🇹🇭🇵🇭🇮🇩🇻🇳🇰🇭🇲🇲🇲🇾🇹🇱🇧🇳🇱🇦🇸🇬 Thank you Dr Freddie Bray, IARC, and our truly #global team. 🔗 thelancet.com/journals/lanon…

Proud of my mentor, Dr Chris Crane, who was awarded the Nobility in Science Award by the National Pancreas Foundation earlier tonight. Dr Crane’s work pioneering ablative radiotherapy for pancreatic cancer has been a game changer for the treatment of locally advanced PDAC!

🧐Our DEPEND trial is out! Neoadjuvant nivo/chemo followed by response-stratified CRT in HPV-negative stage IVa/b HNSCC. UChicagoCancerCenter University of Chicago Hematology/Oncology Aditya Juloori Pearson Lab Nishant Agrawal Evgeny Izumchenko Everett Vokes jamanetwork.com/journals/jamao…

One of my favourite things to do as an academic clinician is to meet the next generation of 🌟trainee #radonc; the future is bright 😎! I was hosted masterfully today Visting Professor at Memorial Sloan Kettering New York. 🗽🍎 Thanks 🙏🏽 Nancy Lee Matthew McMillan, MD for the invite!

We are thrilled to announce the appointment of Alec C. Kimmelman, MD, PhD, as the next Chief Executive Officer at NYU Langone Health and Dean of NYU Grossman School of Medicine effective September 1, 2025. Learn more: nyulangone.org/news/nyu-lango…

Thrilled to announce that Dr. Phuoc Tran will be joining ⁦MD Anderson Cancer Center⁩ as Chair of GU Rad Onc Dept. Can’t wait to see all that you will do to help us #endcancer

Congrats Max Diehn, MD/PhD on this stunning achievement which opens up so many new possibilities for precision oncology. nature.com/articles/s4158…

ICYMI: At #AACR25, Ravindra Uppaluri presented a study led by him and Dr. Douglas Adkins evaluating neoadjuvant & adjuvant #pembrolizumab plus standard of care in resectable locally advanced #headandneckcancer. Nancy Lee was rad onc co-lead. Learn more: bit.ly/4jRCGAV

Insightful synthesis and discussion by Prof Kevin Harrington The Royal Marsden Cancer Charity The Royal Marsden NHS Foundation Trust comparing and contrasting KN630 and C-POST 💡time to start adj IO 🚨effect of ENI? #ASCO25 Shlomo Koyfman Neil D. Gross, MD, FACS

💡Seminal international 🇺🇸🇨🇦 efforts evaluating proactive vs reactive swallowing therapy during HNRT. - No meaningful difference b/w 3 arms ➡️ allows choice based on patient/clinic factors. Congrats Kate Hutcheson Rosemary Martino Neil Woody Princess Margaret Cancer Centre

BREAKING🚨: U.S. FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC #oncology onclive.com/view/fda-appro…

Excellent work here, with successful results consistent with the published literature on 40 Gy (or less) to the elective neck.

In Journal of Clinical Oncology, our reflections on the timely ASCO TORS guideline Nancy Lee Nadeem Riaz 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery